<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01571076</url>
  </required_header>
  <id_info>
    <org_study_id>1112-C-091-CR</org_study_id>
    <nct_id>NCT01571076</nct_id>
  </id_info>
  <brief_title>Preimplantation Genetic Screening (PGS) in Advanced Female Age and Male Severe Factor</brief_title>
  <official_title>Prospective and Randomized Study of the Use of Comparative Genomic Hybridization (CGH) Arrays to Study Embryo Aneuploidies in Female Advanced Age and Male Factor In Vitro Fertilization (IVF) Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Igenomix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Igenomix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preimplantation Genetic Screening (PGS) is used for the selection of chromosomally normal&#xD;
      embryos before the transfer in IVF treatments in many cases. There is great debate in the&#xD;
      scientific community as to whether this is an efficient practice in patients of different&#xD;
      prognosis.&#xD;
&#xD;
      This prospective and randomized study seeks to study the results of chromosomal diagnosis&#xD;
      using the new Comparative Genomic hybridization (CGH) arrays technique by practicing&#xD;
      Preimplantation Genetic Screening (PGS) in day three biopsy on one arm of the study and not&#xD;
      on the other arm in order to compare the results. The investigators will study the ongoing&#xD;
      pregnancy rate of each oocyte retrieval and the ongoing implantation rate with Day 5 embryos&#xD;
      (blastocysts) in IVF/ intracytoplasmic sperm injection (ICSI) treatments of embryos from two&#xD;
      different groups of patients: Advanced Age Female Patients (38 - 41 years of age) and Male&#xD;
      severe factor (≥2 million spermatozoids/ml.).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The randomized controlled trial results of advanced maternal age was completed and published&#xD;
      (Rubio et al., Fertility&amp;Sterility 2017).&#xD;
&#xD;
      The randomized controlled trial results of the male factor indication was terminated with&#xD;
      anticipation due to the change of the technology that prevented recruitment of patients using&#xD;
      the old technology (that one used in the study).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2012</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing Implantation and Pregnancy Rate</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Embryo Aneuploidies</condition>
  <condition>Implantation Rates</condition>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Group B - Severe Male Factor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PGS of day three biopsies and consequent embryo transfer on on Day 5 (blastocyst)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B - Advanced Age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PGS of day three biopsies and consequent embryo transfer on on Day 5 (blastocyst)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A - Advanced Age</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prolonged culture, no PGS, for Day 5 (blastocyst) embryo transfer for the Advanced Age group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A - Severe Male Factor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prolonged culture, no PGS, for Day 5 (blastocyst) embryo transfer for the Severe Male Factor group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>PGS</intervention_name>
    <description>Preimplantation Genetic Screening of the embryos and posterior transfer of ongoing Day 5 blastocysts.</description>
    <arm_group_label>Group A - Severe Male Factor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>PGS</intervention_name>
    <description>Preimplantation Genetic Screening of the embryos and posterior transfer of ongoing Day 5 blastocysts.</description>
    <arm_group_label>Group A - Advanced Age</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Prolonged culture</intervention_name>
    <description>The embryos will be in prolonged culture and on going embryos transferred on Day 5 .</description>
    <arm_group_label>Group B - Advanced Age</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Prolonged culture</intervention_name>
    <description>Prolonged culture of the embryos and posterior transfer of ongoing Day 5 blastocysts.</description>
    <arm_group_label>Group B - Severe Male Factor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: ADVANCED AGE and SEVERE MALE FACTOR:&#xD;
&#xD;
          -  Women's Age: 38- 41 years old (both included)&#xD;
&#xD;
          -  Men's Age: 18-60 years old (both included)&#xD;
&#xD;
          -  Ovulation triggered with human chorionic gonadotrophin (hCG) (Ovitrelle, Merck-Serono,&#xD;
             Madrid)&#xD;
&#xD;
          -  Number of Oocytes metaphase II (MII): ≥ 5 (fresh, not vitrified)&#xD;
&#xD;
          -  Quality of semen: ≥ 5 millions spermatozoids/ml&#xD;
&#xD;
        Exclusion Criteria: ADVANCED AGE and SEVERE MALE FACTOR:&#xD;
&#xD;
          -  Number of Oocytes metaphase II (MII): &lt;5 oocytes&#xD;
&#xD;
          -  Number of Oocytes obtained: &gt;20&#xD;
&#xD;
          -  Estradiol on the day of human chorionic gonadotrophin (hCG) &gt;3000 pgr/ml&#xD;
             administration.&#xD;
&#xD;
          -  Progesterone on the day of hCG &gt;1,5 pmol/l administration&#xD;
&#xD;
          -  ≥ 2 previous miscarriages:biochemical,clinical,ectopic or a combination)&#xD;
&#xD;
          -  Any un corrected alteration in a previous study.&#xD;
&#xD;
          -  Other indications of (Preimplantation Genetic Diagnosis.Screening) PGD-S, such as&#xD;
             monogenic illnesses, translocations, repeated implantation failure, repeated&#xD;
             miscarriages, etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Simon, MDPhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmen Rubio, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Igenomix</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SPAIN: IVI Valencia, IVI Barcelona, IVI Madrid</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>March 29, 2012</study_first_submitted>
  <study_first_submitted_qc>April 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2012</study_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Valenciano de Infertilidad, IVI VALENCIA</investigator_affiliation>
    <investigator_full_name>Carlos Simon</investigator_full_name>
    <investigator_title>Director of Clinical Research IVI Valencia</investigator_title>
  </responsible_party>
  <keyword>PGS</keyword>
  <keyword>CGH</keyword>
  <keyword>Aneuploidy</keyword>
  <keyword>Advanced maternal age</keyword>
  <keyword>Male factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Aneuploidy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

